mRNA Neoantigen Vaccine (Shanghai Regenelead Therapies)

N/A

Report date: 2025/03/07 16:55:43

Base Information

Drug NamemRNA Neoantigen Vaccine (Shanghai Regenelead Therapies)
Drug Alias NameNeoantigen personalized mRNA vaccinesPersonalized Tumour Vaccines
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Regenelead Therapies Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Regenelead Therapies Co LtdFudan University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A